Imaginostics is a health tech startup developing a breakthrough longevity technology for precision medicine. The companys QUTE-CE MRI methodology provides vascular imaging biomarkers that can non-invasively assay vascular structure and function in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. Defining what they do as addressing the need of quantitative imaging biomarkers, the firm's principals note the dearth of non-invasive diagnostic tools for the internal assessment of human physiology. While MRI is among the safest, most non-invasive clinical imaging modalities, it primarily provides clinicians with only qualitative, contrast-based images.No matterthe extent of processing, even with artificial intelligence (AI), there will always be limits due to the qualitative nature of current imaging biomarkers. Until now, the few quantitative biomarkers for MRI are not reliable for single patient precision diagnostics: a desperate need for reliable and accurate measurements of relevant internal physiology
